Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lia Gore

Showing results (1-10 of 119) with videos related to

Pageof 12
Sort By:
Best Practice & Research. Clinical Haematology|December 14, 2022
What are the long-term complications of pediatric ALL treatments and how can they be mitigated? Perspectives on long-term consequences of curative treatment in childhood ALLLia Gore
Hematology. American Society of Hematology. Education Program|December 7, 2019
Moving immunotherapy into the front line in ALLAmanda Winters, Lia Gore
Expert Opinion on Investigational Drugs|September 6, 2011
Entinostat for treatment of solid tumors and hematologic malignanciesJeffrey Knipstein, Lia Gore
Frontiers in Oncology|April 19, 2014
Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE(®) Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric ApplicationsLindsey M Hoffman, Lia Gore
Haematologica|June 4, 2024
Bispecific T-cell engagers in childhood B-acute lymphoblastic leukemiaKaylyn Utley Lyons, Lia Gore
Cell|March 29, 2024
Only the beginning: 50 years of progress toward curing childhood cancerLia Gore, Maureen M O'Brien
Current Hematologic Malignancy Reports|July 20, 2010
Emerging non-transplant-based strategies in treating pediatric non-Hodgkin's lymphomaLia Gore, Tanya M Trippett
Paediatric Drugs|November 17, 2017
Agents in Development for Childhood Acute Lymphoblastic LeukemiaKelly W Maloney, Lia Gore
Paediatric Drugs|March 19, 2014
Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemiaKelly Faulk, Lia Gore, Todd Cooper
Investigational New Drugs|November 4, 2010
Vandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agentsMargaret E Macy, Deborah DeRyckere, Lia Gore
Pageof 12

Showing results (1-10 of 119) with videos related to

Sort By:
Pageof 12
Best Practice & Research. Clinical Haematology|December 14, 2022
What are the long-term complications of pediatric ALL treatments and how can they be mitigated? Perspectives on long-term consequences of curative treatment in childhood ALLLia Gore
Hematology. American Society of Hematology. Education Program|December 7, 2019
Moving immunotherapy into the front line in ALLAmanda Winters, Lia Gore
Expert Opinion on Investigational Drugs|September 6, 2011
Entinostat for treatment of solid tumors and hematologic malignanciesJeffrey Knipstein, Lia Gore
Frontiers in Oncology|April 19, 2014
Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE(®) Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric ApplicationsLindsey M Hoffman, Lia Gore
Haematologica|June 4, 2024
Bispecific T-cell engagers in childhood B-acute lymphoblastic leukemiaKaylyn Utley Lyons, Lia Gore
Cell|March 29, 2024
Only the beginning: 50 years of progress toward curing childhood cancerLia Gore, Maureen M O'Brien
Current Hematologic Malignancy Reports|July 20, 2010
Emerging non-transplant-based strategies in treating pediatric non-Hodgkin's lymphomaLia Gore, Tanya M Trippett
Paediatric Drugs|November 17, 2017
Agents in Development for Childhood Acute Lymphoblastic LeukemiaKelly W Maloney, Lia Gore
Paediatric Drugs|March 19, 2014
Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemiaKelly Faulk, Lia Gore, Todd Cooper
Investigational New Drugs|November 4, 2010
Vandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agentsMargaret E Macy, Deborah DeRyckere, Lia Gore
Pageof 12